Johns Hopkins School of Medicine & Its Lead Investigators Publish Study in NEJM, Co-Authored By Bliss & Next Practice Leaders

The Bliss Group is excited to congratulate our client Johns Hopkins School of Medicine and its lead investigators on the publication of their pivotal study in the New England Journal of Medicine (NEJM) this March. 

As part of Operation Warp Speed, Bliss and the Next Practice Group recruited patients for this clinical trial that was investigating a potential treatment for COVID-19. Time was limited; the COVID-19 Pandemic needed an immediate and scalable treatment option.  

Our founder-led firms at the Next Practices Group formed a common team to create a series of new models, based on media, marketing, and math, that greatly improve the effectiveness of how we accelerate and diversify clinical trial enrollment.  

Bliss’s Michael Roth and The Next Practice’s Colin Foster were included as authors of the study, in recognition of the central role that patient enrollment processes play in a successful clinical trial.  

This remarkable achievement would not be possible without the extraordinary talent and teamwork across the Next Practices Group. A special thank you to Quintin Maidment, Meg Wildrick, Marisha Chinsky, Julia Thuman, David Pierpont, Yash Gad, Chris Chilek, John Cunningham, Desiree Huitt, and Mike Gehb for your hard work and essential expertise. 

The innovative recruitment approach used in the Hopkins trial—known as CTRx Pathways—is now available to researchers nationwide.  

Read "Early Outpatient Treatment for Covid-19 with Convalescent Plasma" here.